NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype
Sign Up to like & getrecommendations! Published in 2020 at "Oncoimmunology"
DOI: 10.1080/2162402x.2020.1845424
Abstract: ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and remains associated with very poor survival. T cell infiltration into tumor tissue is associated with improved clinical outcome but little is… read more here.
Keywords: phenotype; tumor tissue; tumor; cells pancreatic ... See more keywords
Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-5744-8
Abstract: BackgroundWith the increase in cancer survivors, more pancreatic ductal adenocarcinomas (PDACs) are developing as second primary cancers. Whether a prior cancer has an inferior impact on survival outcomes in patients with PDAC remains unknown, and… read more here.
Keywords: outcomes patients; survival outcomes; analysis; patients pdac ... See more keywords
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246223
Abstract: Simple Summary Metastatic pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that has limited treatment options. Standard of care treatment involves systemic chemotherapy, although all tumors invariably develop resistance to these cytotoxic therapies. With the… read more here.
Keywords: metastatic pancreatic; targeted therapies; patients pdac; adenocarcinoma ... See more keywords
Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030897
Abstract: Simple Summary During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this… read more here.
Keywords: ductal adenocarcinoma; value; patients pdac; pancreatic ductal ... See more keywords
ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal
Sign Up to like & getrecommendations! Published in 2025 at "Current Oncology"
DOI: 10.3390/curroncol32110589
Abstract: Simple Summary Detection of cancer derived mutations in blood could offer a more accurate assessment of patient prognosis, their response to therapies, and a better way to monitor the biology of the patients’ cancer and… read more here.
Keywords: oncology; ctdna pancreatic; potential ctdna; patients pdac ... See more keywords
Pretherapeutic factors predicting conversion surgery in unresectable pancreatic ductal adenocarcinoma: A retrospective study
Sign Up to like & getrecommendations! Published in 2024 at "Oncology Letters"
DOI: 10.3892/ol.2024.14304
Abstract: Recently, conversion surgery (CS) has been reported to improve the prognosis in patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC) with a favorable response to intense chemotherapy or chemoradiotherapy. However, few pretherapeutic parameters predict the attainability… read more here.
Keywords: ductal adenocarcinoma; unresectable pancreatic; conversion surgery; patients pdac ... See more keywords